Trial Profile
Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Tocilizumab (Primary) ; Tumour necrosis factor inhibitors (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Acronyms MAZERATI
- 09 Sep 2020 Status changed from active, no longer recruiting to discontinued.
- 03 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 May 2020.
- 03 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 May 2020.